A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer
Clinical trial NCT03674112 · COMPLETED
Trial details
- NCT number
- NCT03674112
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-19
- Primary completion
- 2020-02-24
- Enrollment
- 160
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.